Loading patent…
AssigneeThe Translational Genomics Research Institute
InventorsDavid Engelthaler, Jolene Bowers, James Schupp
Estimating the term…
Methods, kits, and oligonucleotides used in the detection of the coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are disclosed. In some aspects, the oligonucleotides are primers or probes used in the described methods or kits. The oligonucleotide consists of 40 or less nucleotides and has a nucleotide sequence that consists essentially of, or is a variant of, the nucleotide sequence of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the oligonucleotide is modified with an internal spacer or a detectable label. For example, the 5′ terminus is labeled with a fluorophore and the 3′ terminus is complexed to a quencher of fluorescence of said fluorophore. In some embodiments, the nucleotide sequence of the oligonucleotide further comprises a universal tail sequence.
Two pairs of oligonucleotides for amplifying SARS-CoV-2 N and S proteins, each oligonucleotide having a 5′ terminus and a 3′ terminus, wherein the nucleotide sequence of each oligonucleotide consists of 40 or less nucleotides;
A method of detecting the presences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polynucleotides in a biological sample in vitro, comprising:
Dependencies are inferred from the claim text.